The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy

Abstract : The “intended purpose” in all therapeutic exposures is treatment efficacy against malignant disease. The optimization principle (as low as reasonably achievable, ALARA) of article 56, when applied in a therapy situation, states that absorbed doses to nontarget tissues should be kept reasonably low, but not so low as to lose efficacy. We think that this applies above all to the fight against life-threatening cancer. As a consequence, we believe that to adhere to the optimization principle in oncological patients, nuclear medicine therapy should be based on individualized dosimetry.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02379748
Contributeur : Nathalie Salvy-Cordoba <>
Soumis le : lundi 25 novembre 2019 - 18:31:56
Dernière modification le : vendredi 10 janvier 2020 - 21:10:20

Lien texte intégral

Identifiants

Citation

C. Chiesa, K. Sjogreen Gleisner, G. Flux, J. Gear, S. Walrand, et al.. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2017, 44 (11), pp.1783-1786. ⟨10.1007/s00259-017-3707-3⟩. ⟨hal-02379748⟩

Partager

Métriques

Consultations de la notice

26